For US Healthcare Professionals

Getting Patients Started

Krystal Connect provides personalized patient support for your patients during their VYJUVEK treatment journey

The first step to getting your patients started on VYJUVEK via Krystal Connect is to download and fill out the Krystal Connect Enrollment Form.

Download Form
Krystal Connect™ logo

To contact Krystal Connect, please call 1-844-5-KRYSTAL or use our Connect With Us form.

Services Include:

Educating patients about VYJUVEK™

Educating patients about VYJUVEK and living with dystrophic epidermolysis bullosa (DEB)

  • Answer patient questions about VYJUVEK
  • Provide resources and help connect patients with programs about DEB and VYJUVEK
Assist with the insurance process

Providing insurance coverage support

  • Assist with the insurance process, including benefits investigation and prior authorizations
  • Informing patients about potential financial assistance options and eligibility requirements as needed
Supporting treatment logistics

Supporting with treatment logistics

  • Helping patients evaluate appropriate administration site options, either in a healthcare professional setting or in a home setting
  • Sharing information with patients about what to expect, and helping coordinate weekly treatments

The Krystal Connect Team includes Patient Access Liaisons and Community Education Liaisons*:

Community Education Liaisons (CELs)

Patient Access Liaisons (PALs)

PALs can help patients with treatment coordination, and can help with a broad range of topics, such as insurance coverage and financial assistance. PALs are experts in health insurance and helping patients understand the healthcare system.

Patient Access Liaisons (PALs)

Community Education Liaisons (CELs)

CELs have backgrounds in nursing or genetic counseling. They can provide education and help answer questions about DEB and treatment with VYJUVEK. They can share information about programs and events tailored to the DEB community.

*PALs and CELs do not direct patient care or provide medical advice.

View Additional Helpful Forms and Resources

Discover Resources
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.


IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.